INDV as reported
Indivior Pharmaceuticals, Inc. reported $1.33B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed.
$1.33B
Revenue, trailing twelve months · to Q2 2026 · +13% against the twelve months before
- Net Income
- $355M
Net Income · +229% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$111M
Free Cash Flow · −164% year on year · trailing twelve months to Q2 2026
- Op Margin
- 32%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.33B | +13% | Q2 2026 |
| Net Income | $355M | +229% | Q2 2026 |
| EPS | $2.79 | +232% | Q2 2026 |
| Gross Margin | 82% | n/a | Q2 2026 |
| Op Margin | 32% | n/a | Q2 2026 |
| Net Margin | 26% | n/a | Q2 2026 |
| ROE | −155% | n/a | Q2 2026 |
| ROA | 19% | n/a | Q2 2026 |
| ROIC | 371% | n/a | Q2 2026 |
| Free Cash Flow | −$111M | −164% | Q2 2026 |
| P/E | 12.8 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Indivior Pharmaceuticals, Inc. (INDV) - Revenue & ProfitRevenue & ProfitIndivior Pharmaceuticals, Inc. (INDV)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #23 of 28 by Smart Score